Document Detail


Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case.
MedLine Citation:
PMID:  15167167     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment with the anti-tumour necrosis factor alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulising Crohn's disease. Infliximab has been tolerated well, with minimal and short-lived adverse effects. The likelihood of severe reactions to infliximab, such as acute and delayed hypersensitivity infusion reactions, is small; nevertheless, if they do occur, they are life-threatening. We report a case of an anaphylaxis-like reaction in a 22-year-old female with long-standing Crohn's disease. The patient was treated successfully with adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody. Follow-up demonstrated mucosal healing and normalisation of elevated pro-inflammatory cytokine transcripts.
Authors:
Andreas Stallmach; Thomas Giese; Carsten Schmidt; Stefan C Meuer; Stefan S Zeuzem
Related Documents :
23070727 - Iron accumulation in parkinson's disease.
21994347 - Small but smart - micrornas in the center of inflammatory processes during cardiovascul...
17039097 - Crohn's disease arthritis treated with infliximab: an open trial in four patients.
25481317 - National and sub-national prevalence, trend, and burden of end stage renal diseases (es...
17128807 - Occupational diseases in the period of socioeconomic transition in poland.
8045697 - Clinical and radiological features in three cases of pulmonary involvement from recurre...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  16     ISSN:  0954-691X     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-05-28     Completed Date:  2004-09-22     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  627-30     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Marienhospital Altenessen, Essen, Germany. a.stallmach@kken.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anaphylaxis / chemically induced*,  drug therapy
Antibodies, Monoclonal / adverse effects*,  therapeutic use*
Antibodies, Monoclonal, Humanized
Crohn Disease / drug therapy*
Female
Gastrointestinal Agents / adverse effects*
Humans
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Gastrointestinal Agents; 0/infliximab; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation...
Next Document:  Who calls for the ambulance: implications for decision support. A descriptive study from a Swedish d...